Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Sistema PJSFC: Binnopharm Group increases stake in Sintez to 88.6%

12 May 2021 08:00

Sistema PJSFC (SSA) Sistema PJSFC: Binnopharm Group increases stake in Sintez to 88.6% 12-May-2021 / 10:00 MSK Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR), transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.


Binnopharm Group increases stake in Sintez to 88.6%

12 May 2021, Moscow - Sistema PJSFC ("Sistema", the "Corporation" or, together with its subsidiaries and affiliates, the "Group") (LSE: SSA, MOEX: AFKS), a publicly traded Russian investment company, announces that its fully owned subsidiary LLC Sistema Telecom Assets has contributed its 32.4% stake in OJSC Sintez to the authorised capital of LLC Binnopharm Group. Following the transaction, Binnopharm Group has increased its stake in OJSC Sintez to 88.6%.

As a result, the effective stake in Binnopharm Group owned by Sistema together with VTB, Sistema's financial partner in the development of the pharmaceuticals business, now stands at 86.5%. A consortium of investors consisting of the Russian Direct Investment Fund ("RDIF"), the Russia-China Investment Fund (co-founded by RDIF and China Investment Corporation) and leading Middle Eastern funds holds 12.5%, with the remaining 1% owned by a minority shareholder (an individual). 

Binnopharm Group is a full-cycle Russian pharmaceutical holding company that combines five production sites across Russia: JSC Alium (formerly OBL Pharm; Serpukhov district, Moscow region), JSC Binnopharm (two sites at Zelenograd and Krasnogorsk), JSC Sintez (Kurgan) and JSC Biocom (Stavropol). Binnopharm Group companies produce a wide range of drugs in various therapeutic groups and have the largest portfolio of drugs among Russian manufacturers with more than 450 marketing authorisations, including the COVID-19 vaccine Sputnik V.

***

For further information, please visit www.sistema.ru or contact:

Press Service of Sistema

Sergey Kopytov

Phone: +7 (495) 228 15 32

kopytov@sistema.ru

IR Service

Nikolai Minashin

Phone: +7 (495) 730 66 00

n.minashin@sistema.ru

 

Sistema PJSFC is a publicly traded Russian investment company with a diversified portfolio of assets serving over 150 million customers in the sectors of telecommunications, high technology, financial services, retail, paper and packaging, agriculture, real estate, tourism and medical services. The company was founded in 1993. Revenue in 2020 was RUB 691.6 billion; total assets equalled RUB 1.4 trillion as of 31 December 2020. Sistema's global depositary receipts are listed under the "SSA" ticker on the London Stock Exchange. Sistema's ordinary shares are listed under the "AFKS" ticker on the Moscow Exchange. Website: www.sistema.com.

 

 


ISIN:US48122U2042
Category Code:MSCH
TIDM:SSA
LEI Code:213800JSZ2UUK4QQK694
Sequence No.:104444
EQS News ID:1195434
 
End of AnnouncementEQS News Service

UK Regulatory announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.